Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue

  • Morón-López, Sara
  • Puertas, Maria C.
  • Gálvez, Cristina
  • Navarro Mercadé, Jordi
  • Carrasco, Anna
  • Crespo Casal, Manuel
  • Esteve, Maria
Biòpsia; VIH-1; Teixit limfoide, Biopsia; VIH-1; Tejido linfoide, Biopsy; HIV-1; Lymphoid tissue, Background The implementation of successful strategies to achieve an HIV cure has become a priority in HIV research. However, the current location and size of HIV reservoirs is still unknown since there are limited tools to evaluate HIV latency in viral sanctuaries such as gut-associated lymphoid tissue (GALT). As reported in the so called “Boston Patients”, despite undetectable levels of proviral HIV-1 DNA in blood and GALT, viral rebound happens in just few months after ART interruption. This fact might imply that current methods are not sensitive enough to detect residual reservoirs. Showing that, it is imperative to improve the detection and quantification of HIV-1 reservoir in tissue samples. Herein, we propose a novel non-enzymatic protocol for purification of Lamina Propria Leukocytes (LPL) from gut biopsies combined to viral HIV DNA (vDNA) quantification by droplet digital PCR (ddPCR) to improve the sensitivity and accuracy of viral reservoir measurements (LPL-vDNA assay). Methods Endoscopic ileum biopsies were sampled from 12 HIV-1-infected cART-suppressed subjects. We performed a DTT/EDTA-based treatment for epithelial layer removal followed by non-enzymatic disruption of the tissue to obtain lamina propria cell suspension (LP). CD45+ cells were subsequently purified by flow sorting and vDNA was determined by ddPCR. Results vDNA quantification levels were significantly higher in purified LPLs (CD45+) than in bulk LPs (p<0.01). The levels of vDNA were higher in ileum samples than in concurrent PBMC from the same individuals (p = 0.002). As a result of the increased sensitivity of this purification method, the Poisson 95% confidence intervals of the vDNA quantification data from LPLs were narrower than that from bulk LPs. Of note, vDNA was unambiguously quantified above the detection limit in 100% of LPL samples, while only in 58% of bulk LPs. Conclusion We propose an innovative combined protocol for a more sensitive detection of the HIV reservoir in gut-associated viral sanctuaries, which might be used to evaluate any proposed eradication strategy., This substudy was supported by ViiV and the American Foundation for AIDS Research (amfAR) (ARCHE). IrsiCaixa was supported by the CERCA programme from Generalitat de Catalunya. MS was supported by the post-doctoral training scholarship (Juan de la Cierva) of the Spanish Economy and Competitiveness Ministry (FPDI-2013-17134). SM-L received a fellowship from the Agència de Gestió d’Ajuts Universitaris i de Recerca (2013FI_B 00275). CG was partially supported by the pre-doctoral fellowship of the Spanish Education, Culture and Sport Ministry (FPU15/03698). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue

  • Moron-Lopez, Sara|||0000-0003-0800-9205
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Navarro, Jordi|||0000-0002-7187-0367
  • Carrasco-Rozas, Ana|||0000-0003-2165-8162
  • Esteve, Maria|||0000-0001-7716-0027
  • Manyè, Josep
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • Salgado, Maria|||0000-0003-1551-7216
  • Martinez Picado, Javier
Background. The implementation of successful strategies to achieve an HIV cure has become a priority in HIV research. However, the current location and size of HIV reservoirs is still unknown since there are limited tools to evaluate HIV latency in viral sanctuaries such as gut-associated lymphoid tissue (GALT). As reported in the so called "Boston Patients", despite undetectable levels of proviral HIV-1 DNA in blood and GALT, viral rebound happens in just few months after ART interruption. This fact might imply that current methods are not sensitive enough to detect residual reservoirs. Showing that, it is imperative to improve the detection and quantification of HIV-1 reservoir in tissue samples. Herein, we propose a novel nonenzymatic protocol for purification of Lamina Propria Leukocytes (LPL) from gut biopsies combined to viral HIV DNA (vDNA) quantification by droplet digital PCR (ddPCR) to improve the sensitivity and accuracy of viral reservoir measurements (LPL-vDNA assay). Methods. Endoscopic ileum biopsies were sampled from 12 HIV-1-infected cART- suppressed subjects. We performed a DTT/EDTA-based treatment for epithelial layer removal followed by non-enzymatic disruption of the tissue to obtain lamina propria cell suspension (LP). CD45+ cells were subsequently purified by flow sorting and vDNA was determined by ddPCR. Results. vDNA quantification levels were significantly higher in purified LPLs (CD45+) than in bulk LPs (p<0.01). The levels of vDNA were higher in ileum samples than in concurrent PBMC from the same individuals (p = 0.002). As a result of the increased sensitivity of thispurification method, the Poisson 95% confidence intervals of the vDNA quantification data from LPLs were narrower than that from bulk LPs. Of note, vDNA was unambiguously quantified above the detection limit in 100% of LPL samples, while only in 58% of bulk LPs. Conclusion. We propose an innovative combined protocol for a more sensitive detection of the HIV reservoir in gut-associated viral sanctuaries, which might be used to evaluate any proposed eradication strategy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Switching From a Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen, A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy-suppressed Human Immunodeficiency Virus-infected Individuals

  • Moron-Lopez, Sara|||0000-0003-0800-9205
  • Navarro, Jordi|||0000-0002-7187-0367
  • Jimenez, Montse
  • Rutsaert, Sofie
  • Urrea, Víctor|||0000-0002-2577-856X
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Torrella Domingo, Adriana|||0000-0003-1848-5096
  • De Clercq, Laura
  • Ribas, Bibiana Planas
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Salgado, Maria|||0000-0003-1551-7216
  • Vandekerckhove, Linos|||0000-0002-8600-1631
  • Blanco, Julià|||0000-0002-2225-0217
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
Optimization of combination antiretroviral therapy (cART) can impact the human immunodeficiency virus (HIV) reservoir. We evaluated the effect on the HIV reservoir in peripheral blood and ileum biopsies in patients switching from boosted protease inhibitor (PI/r)-based therapy to dolutegravir (DTG)-based therapy. Impact of Integrase-inhibitor DOlutegravir On the viral Reservoir (INDOOR) is a phase 4 open-label clinical trial that randomly included 42 HIV type 1-infected individuals on effective cART: 20 who switched from PI/r-based to DTG-based cART (switch group), and 22 who remained in PI/r-based regimens (control group). We analyzed blood and ileum biopsies to quantify episomal, total, and integrated HIV DNA, cell-associated HIV RNA, residual plasma viremia, T-cell subsets, cell activation, and inflammation markers. There were no related adverse events or treatment discontinuations due to drug intolerance. The HIV reservoir was consistently larger in ileal than in peripheral CD4 + T cells in both groups (P <.01). Residual viremia in plasma decreased in the switch group (P =.03). However, we did not observe significant longitudinal changes in low-level viral replication, total and integrated HIV reservoir, HIV transcription, T-cell maturation subsets, immunoactivation markers, inflammatory soluble proteins, or cellular markers of latently infected cells. The INDOOR study is the first evaluation of changes in HIV reservoir size in ileum biopsies and in peripheral blood in individuals switched from PI/r- to DTG-based cART. Although this switch was safe and well tolerated, it had no impact on a large array of immunological and inflammatory markers or on HIV reservoir markers in peripheral or in ileal CD4 + T cells. EudraCT 2014-004331-39. INDOOR evaluated the effect of switching from boosted protease inhibitor- to dolutegravir-based antiretroviral therapy on the HIV reservoir in peripheral blood and ileum. Residual plasma viremia and soluble CD14 levels decreased, but low-level HIV replication, the HIV reservoir, and immune activation remained unaffected.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Extremely low viral reservoir in treated chronically HIV-1-infected individuals

  • Gálvez, Cristina|||0000-0002-2286-6193
  • Urrea, Víctor|||0000-0002-2577-856X
  • Dalmau, Judith|||0000-0001-7513-3711
  • Jiménez Valero, Montserrat|||0000-0003-2919-7604
  • Pérez-Álvarez, Núria|||0000-0001-6582-1553
  • Monceaux, Valérie|||0000-0002-8599-2146
  • Huot, Nicolas
  • Leal, Lorna|||0000-0001-7887-6027
  • González Soler, Victoria|||0000-0002-0983-2052
  • González-Cao, María|||0000-0003-3791-540X
  • Müller-Trutwin, Michaela
  • Sáez-Cirión, Asier|||0000-0003-2406-7536
  • García, Felipe|||0000-0001-7658-5832
  • Blanco, Julià|||0000-0002-2225-0217
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Salgado, Maria|||0000-0003-1551-7216
Small viral reservoirs are found predominantly in HIV-1 controllers and individuals treated during acute/early HIV-1 infection. However, other HIV + individuals could naturally also harbour low viral reservoirs. We screened 451 HIV-1-infected treated-individuals with suppressed plasma viremia for at least 3 years and stored cryopreserved peripheral blood mononuclear cells (PBMCs). Total HIV-DNA was analysed in PBMCs with ddPCR. Individuals with <50 HIV-DNA copies/10 6 PBMCs constitute the 'Low Viral Reservoir Treated' cohort (LoViReT). Longitudinal samples were obtained from 12 chronically treated LoViReT and compared to 13 controls (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC1 null variant that limits antigen exchange via trafficking extracellular vesicles

  • Benet, Susana|||0000-0002-2219-8826
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Drobniewski, Francis
  • Kontsevaya, Irina
  • Arias, Lilibeth|||0000-0002-2469-8832
  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Urrea, Víctor|||0000-0002-2577-856X
  • Ong, Ruo-Yan
  • Luquin Fernandez, Marina de la Milagrosa|||0000-0002-6015-3282
  • Dupont, Maeva|||0000-0002-0514-4447
  • Chojnacki, Jakub|||0000-0002-4457-8096
  • Dalmau, Judith|||0000-0001-7513-3711
  • Cardona, Paula|||0000-0002-8613-9390
  • Neyrolles, Olivier|||0000-0003-0047-5885
  • Lugo-Villarino, Geanncarlo|||0000-0003-4620-8491
  • Vérollet, Christel|||0000-0002-1079-9085
  • Julián, Esther|||0000-0002-6558-3978
  • Furrer, Hansjakob
  • Günthard, Huldrych F.
  • Crocker, Paul R.
  • Tapia, Gustavo|||0000-0003-1882-0368
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Fellay, Jacques|||0000-0002-8240-939X
  • McLaren, Paul J.
  • Telenti, Amalio
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • Pérez-Álvarez, Núria|||0000-0001-6582-1553
  • Vilaplana Massaguer, Cristina|||0000-0002-2808-7270
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
The identification of individuals with null alleles enables studying how the loss of gene function affects infection. We previously described a non-functional variant in SIGLEC1, which encodes the myeloid-cell receptor Siglec-1/CD169 implicated in HIV-1 cell-to-cell transmission. Here we report a significant association between the SIGLEC1 null variant and extrapulmonary dissemination of Mycobacterium tuberculosis (Mtb) in two clinical cohorts comprising 6,256 individuals. Local spread of bacteria within the lung is apparent in Mtb-infected Siglec-1 knockout mice which, despite having similar bacterial load, developed more extensive lesions compared to wild type mice. We find that Siglec-1 is necessary to induce antigen presentation through extracellular vesicle uptake. We postulate that lack of Siglec-1 delays the onset of protective immunity against Mtb by limiting antigen exchange via extracellular vesicles, allowing for an early local spread of mycobacteria that increases the risk for extrapulmonary dissemination.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and T-cell responses associated with natural HIV control

  • Oriol-Tordera, Bruna|||0000-0002-2714-9097
  • Berdasco, Maria|||0000-0002-6750-0400
  • Llano Montero, Anuska|||0000-0002-0133-9888
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Blanco, Julià|||0000-0002-2225-0217
  • Duran-Castells, Clara|||0000-0002-4034-5738
  • Ganoza, C.
  • Sanchez, Jorge
  • Pérez-Álvarez, Núria|||0000-0001-6582-1553
  • Calle, M. Luz|||0000-0001-9334-415X
  • Sánchez, Alex|||0000-0002-8673-7737
  • Esteller, M.|||0000-0003-4490-6093
  • Brander, Christian|||0000-0002-0548-5778
  • Ruiz Riol, Marta|||0000-0003-1899-8879
GWAS, immune analyses and biomarker screenings have identified host factors associated with in vivo HIV-1 control. However, there is a gap in the knowledge about the mechanisms that regulate the expression of such host factors. Here, we aimed to assess DNA methylation impact on host genome in natural HIV-1 control. To this end, whole DNA methylome in 70 untreated HIV-1 infected individuals with either high (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Enhancement of Antiviral CD8 + T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab

  • Blanch-Lombarte, Oscar|||0000-0002-8317-7535
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Revollo, Boris|||0000-0001-9245-2183
  • Jiménez-Moyano, Esther|||0000-0002-0005-6544
  • Llibre Codina, Josep Maria|||0000-0002-7158-6753
  • Manzano, José Luís
  • Boada, Aram|||0000-0001-9809-5308
  • Dalmau, Judith|||0000-0001-7513-3711
  • E. Speiser, Daniel
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • G. Prado, Julia
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
Background: Pembrolizumab is an immune checkpoint inhibitor against programmed cell death protein-1 (PD-1) approved for therapy in metastatic melanoma. PD-1 expression is associated with a diminished functionality in HIV-1 specific-CD8 + T cells. It is thought that PD-1 blockade could contribute to reinvigorate antiviral immunity and reduce the HIV-1 reservoir. Methods: Upon metastatic melanoma diagnosis, an HIV-1-infected individual on stable suppressive antiretroviral regimen was treated with pembrolizumab. A PET-CT was performed before and one year after pembrolizumab initiation. We monitored changes in the immunophenotype and HIV-1 specific-CD8 + T-cell responses during 36 weeks of treatment. Furthermore, we assessed changes in the viral reservoir by total HIV-1 DNA, cell-associated HIV-1 RNA, and ultrasensitive plasma viral load. Results: Complete metabolic response was achieved after pembrolizumab treatment of metastatic melanoma. Activated CD8 + T-cells expressing HLA-DR + /CD38 + transiently increased over the first nine weeks of treatment. Concomitantly, there was an augmented response of HIV-1 specific-CD8 + T cells with TNF production and poly-functionality, transitioning from TNF to an IL-2 profile. Furthermore, a transient reduction of 24% and 32% in total HIV-1 DNA was observed at weeks 3 and 27, respectively, without changes in other markers of viral persistence. Conclusions: These data demonstrate that pembrolizumab may enhance the HIV-1 specific-CD8 + T-cell response, marginally affecting the HIV-1 reservoir. A transient increase of CD8 + T-cell activation, TNF production, and poly-functionality resulted from PD-1 blockade. However, the lack of sustained changes in the viral reservoir suggests that viral reactivation is needed concomitantly with HIV-1-specific immune enhancement.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction

  • Duran-Castells, Clara|||0000-0002-4034-5738
  • Llano Montero, Anuska|||0000-0002-0133-9888
  • Kawana-Tachikawa, Ai|||0000-0002-3082-5324
  • Prats, Anna|||0000-0002-3586-4525
  • Martinez-Zalacain, Ignacio
  • Kobayashi-Ishihara, Mie|||0000-0001-6342-9451
  • Oriol-Tordera, Bruna|||0000-0002-2714-9097
  • Peña, Ruth
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Silva-Arrieta, Sandra
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Ballana, Ester|||0000-0002-5215-7363
  • Prado, Julia G.|||0000-0002-5439-4645
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Sanchez, Jorge
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Hartigan-O'Connor, Dennis
  • Wyss-Coray, Tony
  • Meyerhans, Andreas|||0000-0003-0620-5317
  • Gisslén, Magnus
  • Price, Richard W.
  • Soriano-Mas, Carles|||0000-0003-4574-6597
  • Muñoz-Moreno, José Antonio|||0000-0002-7239-5422
  • Brander, Christian|||0000-0002-0548-5778
  • Ruiz Riol, Marta|||0000-0003-1899-8879
The implementation and access to combined antiretroviral treatment (cART) have dramatically improved the quality of life of people living with HIV (PLWH). However, some comorbidities, such as neurological disorders associated with HIV infection still represent a serious clinical challenge. Soluble factors in plasma that are associated with control of HIV replication and neurological dysfunction could serve as early biomarkers and as new therapeutic targets for this comorbidity. We used a customized antibody array for determination of blood plasma factors in 40 untreated PLWH with different levels of viremia and found sirtuin-2 (SIRT2), an NAD-dependent deacetylase, to be strongly associated with elevated viral loads and HIV provirus levels, as well as with markers of neurological damage (a-synuclein [SNCA], brain-derived neurotrophic factor [BDNF], microtubule-associated protein tau [MAPT], and neurofilament light protein [NFL]). Also, longitudinal analysis in HIV-infected individuals with immediate (n = 9) or delayed initiation (n = 10) of cART revealed that after 1 year on cART, SIRT2 plasma levels differed between both groups and correlated inversely with brain orbitofrontal cortex involution. Furthermore, targeting SIRT2 with specific small-molecule inhibitors in in vitro systems using J-LAT A2 and primary glial cells led to diminished HIV replication and virus reactivation from latency. Our data thus identify SIRT2 as a novel biomarker of uncontrolled HIV infection, with potential impact on neurological dysfunction and offers a new therapeutic target for HIV treatment and cure. IMPORTANCE Neurocognitive disorders are frequently reported in people living with HIV (PLWH) even with the introduction of combined antiretroviral treatment (cART). To identify biomarkers and potential therapeutic tools to target HIV infection in peripheral blood and in the central nervous system (CNS), plasma proteomics were applied in untreated chronic HIV-infected individuals with different levels of virus control. High plasma levels of sirtuin-2 (SIRT2), an NAD + deacetylase, were detected in uncontrolled HIV infection and were strongly associated with plasma viral load and proviral levels. In parallel, SIRT2 levels in the peripheral blood and CNS were associated with markers of neurological damage and brain involution and were more pronounced in individuals who initiated cART later in infection. In vitro infection experiments using specific SIRT2 inhibitors suggest that specific targeting of SIRT2 could offer new therapeutic treatment options for HIV infections and their associated neurological dysfunction.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Altered T-cell subset distribution in the viral reservoir in HIV-1-infected individuals with extremely low proviral DNA (LoViReTs)

  • Gálvez, Cristina|||0000-0002-2286-6193
  • Urrea, Víctor|||0000-0002-2577-856X
  • García Guerrero, María del Carmen|||0000-0001-7651-7629
  • Bernal, Sílvia
  • Benet, Susana|||0000-0002-2219-8826
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Bailón, Lucía|||0000-0001-7277-9314
  • Dalmau, Judith|||0000-0001-7513-3711
  • Martinez, Andrea
  • Nieto Gil-Ortega, Aroa|||0000-0001-8477-5062
  • Leal, Lorna|||0000-0001-7887-6027
  • García, Felipe|||0000-0001-7658-5832
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Salgado, Maria|||0000-0003-1551-7216
HIV cure strategies aim to eliminate viral reservoirs that persist despite successful antiretroviral therapy (ART). We have previously described that 9% of HIV-infected individuals who receive ART harbor low levels of provirus (LoViReTs). We selected 22 LoViReTs matched with 22 controls ART suppressed for more than 3 years with fewer than 100 and more than 100 HIV-DNA copies/10 6 CD4 + T cells, respectively. We measured HIV reservoirs in blood and host genetic factors. Fourteen LoViReTs underwent leukapheresis to analyze replication-competent virus, and HIV-DNA in CD4 + T-cell subpopulations. Additionally, we measured HIV-DNA in rectum and/or lymph node biopsies from nine of them. We found that LoViReTs harbored not only lower levels of total HIV-DNA, but also significantly lower intact HIV-DNA, cell-associated HIV-RNA, and ultrasensitive viral load than controls. The proportion of intact versus total proviruses was similar in both groups. We found no differences in the percentage of host factors. In peripheral blood, 71% of LoViReTs had undetectable replication-competent virus. Minimum levels of total HIV-DNA were found in rectal and lymph node biopsies compared with HIV-infected individuals receiving ART. The main contributors to the reservoir were short-lived transitional memory and effector memory T cells (47% and 29%, respectively), indicating an altered distribution of the HIV reservoir in the peripheral T-cell subpopulations of LoViReTs. In conclusion, LoViReTs are characterized by low levels of viral reservoir in peripheral blood and secondary lymphoid tissues, which might be explained by an altered distribution of the proviral HIV-DNA towards more short-lived memory T cells. LoViReTs can be considered exceptional candidates for future interventions aimed at curing HIV.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue

  • Morón-López, Sara
  • Puertas, Maria C.
  • Gálvez, Cristina
  • Navarro Mercadé, Jordi
  • Carrasco, Anna
  • Crespo Casal, Manuel
  • Esteve, Maria
Biòpsia; VIH-1; Teixit limfoide, Biopsia; VIH-1; Tejido linfoide, Biopsy; HIV-1; Lymphoid tissue, Background The implementation of successful strategies to achieve an HIV cure has become a priority in HIV research. However, the current location and size of HIV reservoirs is still unknown since there are limited tools to evaluate HIV latency in viral sanctuaries such as gut-associated lymphoid tissue (GALT). As reported in the so called “Boston Patients”, despite undetectable levels of proviral HIV-1 DNA in blood and GALT, viral rebound happens in just few months after ART interruption. This fact might imply that current methods are not sensitive enough to detect residual reservoirs. Showing that, it is imperative to improve the detection and quantification of HIV-1 reservoir in tissue samples. Herein, we propose a novel non-enzymatic protocol for purification of Lamina Propria Leukocytes (LPL) from gut biopsies combined to viral HIV DNA (vDNA) quantification by droplet digital PCR (ddPCR) to improve the sensitivity and accuracy of viral reservoir measurements (LPL-vDNA assay). Methods Endoscopic ileum biopsies were sampled from 12 HIV-1-infected cART-suppressed subjects. We performed a DTT/EDTA-based treatment for epithelial layer removal followed by non-enzymatic disruption of the tissue to obtain lamina propria cell suspension (LP). CD45+ cells were subsequently purified by flow sorting and vDNA was determined by ddPCR. Results vDNA quantification levels were significantly higher in purified LPLs (CD45+) than in bulk LPs (p<0.01). The levels of vDNA were higher in ileum samples than in concurrent PBMC from the same individuals (p = 0.002). As a result of the increased sensitivity of this purification method, the Poisson 95% confidence intervals of the vDNA quantification data from LPLs were narrower than that from bulk LPs. Of note, vDNA was unambiguously quantified above the detection limit in 100% of LPL samples, while only in 58% of bulk LPs. Conclusion We propose an innovative combined protocol for a more sensitive detection of the HIV reservoir in gut-associated viral sanctuaries, which might be used to evaluate any proposed eradication strategy., This substudy was supported by ViiV and the American Foundation for AIDS Research (amfAR) (ARCHE). IrsiCaixa was supported by the CERCA programme from Generalitat de Catalunya. MS was supported by the post-doctoral training scholarship (Juan de la Cierva) of the Spanish Economy and Competitiveness Ministry (FPDI-2013-17134). SM-L received a fellowship from the Agència de Gestió d’Ajuts Universitaris i de Recerca (2013FI_B 00275). CG was partially supported by the pre-doctoral fellowship of the Spanish Education, Culture and Sport Ministry (FPU15/03698). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.